The current members of the IFAPP Board of Officers are listed below. This Board will serve a two-year term, from 2018 to 2020, at the conclusion of which the House of Delegates will elect a new Board.
If you wish to contact any member of the Board of Officers below please get in touch with:
2411 CL Bodegraven
Phone: +31 6 2291 1039
Chamber of Commerce: 30224375
Dr Imamura graduated from Kumamoto University Medical School in 1982, and started resident training at Department of Orthopedic Surgery, Jikei University School of Medicine, Tokyo. She obtained a Dr of Medical Science (in Cellular Biology) from Jikei University School of Medicine in 1989, upon completion of study experience in clinical pharmacology at Dana Farber Cancer Institute, Harvard Medical School, USA. She also obtained a PhD (in Outcomes Research) from the London School of Hygiene and Tropical Medicine, University of London, UK, in 1995. She has a vast experience in medicines development and marketing in pharmaceutical companies (foreign-based) and Contract Research Organizations in Japan since 1995.
After a series of practices from basic science, clinical orthopedics and outcomes research, Dr Imamura built her career in the pharmaceutical industry by taking leading roles in Research and Development (R&D) and Medical Affairs. Since November 2018 she has been conducting research projects as the project professor of the Social Cooperation Program of IT Healthcare at the University of Tokyo.
Dr Imamura had three roles for her contribution to Pharmaceutical Medicine as a discipline and a profession as Chairperson of JAPhMed (Japanese Association of Pharmaceutical Medicine) until July 2015, and she has been active in promoting the medical perspectives and responsibilities in R&D and product life-cycle management. As a member of the Board of Directors for ACRP, Japan (ACRP: Association of Clinical Research Professionals) she promoted talent development of CRCs (Clinical Research Coordinators) and CRAs (Clinical Research Associates) involved in global clinical studies.
Dr Marco Romano has been Executive Director at Chiltern International since 2007. In this position Dr Romano has full responsibility within the Medical Department including Clinical Development, Medical Support and Clinical Operations, Medical Monitoring and Medical Support and Pharmacovigilance Services.
Dr Romano has over 30 years of medicines development experience, both in pharmaceutical companies and in clinical research organizations. He has successfully managed a number of Phase II, III and IV clinical trials and, since 1998 has held senior management positions within the Clinicarl Research Organization sector such as Country Manager, Medical Director, and Chief Medical Officer.
Dr Romano obtained his degree in Medicine at the University of Genoa, Italy, in 1983. He then obtained a postgraduate degree in Hygiene, Epidemiology and Public Health in 1987 and a further postgraduate degree in Clinical Pharmacology in 1994.
Dr Romano is the co-author of several scientific papers concerning mutagenesis and carcinogenesis, pharmacokinetics and pharmacodynamics of chemical compounds and glutathione metabolism. He has been a member of the Italian Medical Association since 1983 and, from May 2014, he has been President of the Society for Applied Pharmacological Sciences (SSFA).
Dr Silva serves as Director of the IFAPP - King's College Professional Certification Program for Medical Affairs in Medicines Development as well as in the Strategic Oversight Committee, Faculty of Pharmaceutical Medicine, Royal Colleges of Physicians UK. He has served on the boards of several academic and professional organizations related to medical education, continuing professional development, clinical research and pharmaceutical medicine.
Dr Silva has served in the pharmaceutical industry for 30 years. He retired as Vice President, Science and Medical Professional Development, within the External Medical Affairs group of Pfizer, Inc. Dr Silva began his career as a Medical Director, Pfizer, Venezuela, before transferring to Pfizer’s New York headquarters (USA). He then served as Vice President, Medical and Regulatory Affairs, Japan, Asia, Africa and Latin America. He began his medical education in Argentina, and received postgraduate training in Internal Medicine and Clinical Pharmacology in Argentina and Venezuela, respectively. He was actively involved in Clinical Research as part of his previous academic activities as Assistant Professor of Clinical Pharmacology, Razetti Medical School, Universidad Central de Venezuela.
Dr Silva has authored or co-authored more than 100 publications on cardiovascular disease, arterial hypertension, infectious diseases, clinical pharmacology and outcomes-based medical education. While serving as President for both the Board of the Venezuelan Society of Clinical Pharmacology and the Venezuelan Society of Pharmacology, he pioneered CME/CPD activities in Venezuela and Latin America (CME/CPD: continuing medical education/continuing professional development). He also pioneered online postgraduate education and CPD programs in Clinical Research, Cardiovascular Risk and Pharmaceutical Medicine across continents.
Dr Silva was pivotal in the creation and development of a number of International Medical Societies and non-profit organizations and has established multiple strategic alliances between medical associations, academic institutions and the pharmaceutical industry aimed at advancing and improving health care internationally. He received several awards for his contributions to Clinical Rresearch and medical education.
Dr Brigitte Franke-Bray FFPM RCP UK1 is an independent consultant and a board-certified specialist in Pharmaceutical Medicine (FMH2/Switzerland). After her medical studies, she worked for several years in a German hospital (Internal Medicine, Pneumology, Allergology) before she joined the pharmaceutical industry.
After 10 years’ work as an international medical expert for respiratory diseases in Ciba-Geigy/Sandoz, Basel, Switzerland, she became the first Office Head/Medical Director for Quintiles in Switzerland and, additionally, headed two more Quintiles offices in Germany.
After about 8 years in these positions she worked as Medical Director for two Swiss companies before she joined the DIA (Drug Information Association) as the Director Europe, Middle East, Africa where she was also responsible as the global Training Director for the development of scientific congresses and training courses in Pharmaceutical Medicine which she designed in collaboration with regulatory medicines agencies such as Swissmedic, CFDA (China), PMDA (Japan), FDA (USA), EMA (EU), the European Commission and also the corresponding institutions/ministries of health in the Middle East and Africa.
After approximately another 8 years Dr. Franke-Bray became a clinical reviewer with Swissmedic, the Swiss Medicines Regulatory Agency before she worked for several years as a globally acting Medical Director in Novartis Basel, responsible for the development of medicines in respiratory diseases.
For 22 years Dr Franke-Bray was a board member of SGPM (Swiss Society of Pharmaceutical Medicine) and of SwAPP (Swiss Association of Pharmaceutical Professionals) and she organized their joint annual symposium every year for 20 years. Dr Franke-Bray is also a member of the examination committee of the University of Basel, Switzerland, for the board certification of physicians in Pharmaceutical Medicine as well as of various other related Basel University diplomas and certificates, e.g. for ECPM, the European Course in Pharmaceutical Medicine.
Dr Franke-Bray collaborated in two of the EU Commission’s IMI (Innovative Medicine Initiative) projects, PharmaTrain (www.pharmatrain.eu) and EUPATI (www.eupati.eu) where she deepened her knowledge of training course development in Pharmaceutical Medicine.
1 Fellow of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians United Kingdom
2 Foederatio Medicorum Helveticorum
Dr Kotone Matsuyama is currently a Professor at the Department of Health Policy and Management and Vice President of the Center for Strategic Research Initiative, Nippon Medical School, Japan. She is also a Project Coordinator in Clinical Development in the Program for Drug Discovery and Medical Technology Platforms, RIKEN Research Cluster for Innovation, an Adjunct Lecturer in Clinical Pharmacology of the Faculty of Medicine, Oita University, and an Adjunct Lecturer of Bioethics, Faculty of Medicine, Kyoto Prefectural University of Medicine. She has been a member of the Board of Directors of JAPhMed (Japanese Association of Pharmaceutical Medicine) since October 2018.
Dr Matsuyama started her Research and Development career as a data manager in 2003 and she has worked as a project manager since 2005. She spent 12 years at the Translational Research Informatics Center, Foundation for Biomedical Research and Innovation, in Kobe, and 2.5 years as Lecturer at the Center for Quality Assurance in Research and Development, Kyoto Prefectural University of Medicine, both in Japan. She has managed or supported many Research and Development projects initiated from academia, not only for medicinal drugs, but also for medical devices and regenerative medicines. Her speciality is process optimization throughout a project recently known as a clinical planning method using Quality by Design. She won awards of excellence at the 36th Annual Congress of the Japanese Society of Clinical Pharmacology and Therapeutics, and at the 7th Annual Congress of the Japanese Society of Clinical Trials and Research. She graduated from Kyoto University, Faculty of Pharmaceutical Science and obtained a license as a Pharmacist.
Dr Criscuolo graduated in Medicine and obtained a PhD in Haematology and Clinical Oncology. He started his career as a Pharmaceutical Physician in 1975 and, in more than 40 years, he held key positions in Big Pharma (Lepetit, Roche), in Biotech companies (Novuspharma, Creabilis) and in Contract Research Organizations (Premier Research, ICON). In 2007 he became a co-founder of Genovax, a Biotech company whose mission is to discover and develop therapeutic vaccines for chronic diseases.
Dr Criscuolo is a Past President of SIMeF (the Italian Association of Pharmaceutical Medicine) and a Past President of IFAPP. He devotes most of his time to educational programs in Pharmaceutical Medicine, teaching at various master courses at Italian Universities. He is also a Visiting Professor at King’s College, London, United Kingdom.
Dr François-Xavier Frapaise has over 38 years of experience in international medicines development, strategic planning and marketing of major pharmaceutical companies including Sanofi, Bayer, Boehringer, Merck and Abbott. He held multiple C-level positions (CSO, CMO, CEO) in different pharmaceutical companies in the USA and Europe. Until recently he was Head of Clinical Development, Medical Affairs and Pharmacovigilance at Merck KGaA, Biosimilars Division. Dr Frapaise has extensive experience in biosimilars development acquired at Boehringer-Ingelheim and Pfenex. He now runs a consulting business based in Paris.
Dr Frapaise was CSO and SVP of Optimer, served as the CEO of Asphelia Pharmaceuticals Inc., was VP of Research and Development and Corporate Officer of TAP, CMO of Ocera Therapeutics, VP of Scientific Affairs at Abbott International , Head of Medical Affairs at Bayer Europe, Medical Director at Bayer France, VP of Research and Development at Delagrange, Head of Anti-thrombotics Strategic Marketing at Sanofi, and Medical Director at Choay.
Dr Frapaise holds a medical degree from the Faculté de Médecine Paris, France, and also an academic position at the Thrombosis Research Center at the Loyola Medical Center in Maywood (IL), USA. He is an INSEAD alumnus. He is the current President of AMMIS (French Association of Pharmaceutical Medicine) and is part of the Leadership team of Trestle Compliance based in Boston, USA.
Dr Kesselring received his medical degree from the University of São Paulo, Brazil, and pursued further postgraduate training in Gynecology, Obstetrics, and Mastology. He also received postgraduate qualifications in Clinical Pharmacology, Drug Development, and Regulation at the Tufts Institute for Professional Development, USA.
For the past three decades, Dr Kesselring has been intimately involved in Clinical Research for both the public and the private sector in Brazil as well as internationally. He was Director of Clinical Research for several multinational pharmaceutical companies in his country. He was appointed Director of the National Clinical Research Training Program for the Ministry of Health in Brazil while serving at the same time as Director of Clinical Research at the Science Institute, German Hospital Oswaldo Cruz, São Paulo, Brazil.
From 2010 until 2015 Dr Kesselring was Executive Director Latin America of the ViS Research Institute which optimizes drug development by enabling access to a complete map of global Clinical Research Infrastructure. ViS was then part of IMS Health.
Dr Kesselring served as an advisor for the World Medical Association for the revision of the Declaration of Helsinki (versions 2008 and 2013). He received awards from the American Academy of Clinical Research Professionals in 2011 and from the Drug Information Association in 2013 in recognition for his contributions to global Clinical Research and Pharmaceutical Medicine.
Dr Kesselring published several articles on Clinical Research and medicines development and was a speaker and chairperson at international conferences in the USA, Europe, Latin America, and Asia.
Dr Kerpel-Fronius obtained his medical diploma and board certifications in Clinical Laboratory Sciences and Clinical Pharmacology at Semmelweis University in Budapest Hungary. He developed an extensive work experience in experimental research in neurobiology first at Semmelweis University, then at the Karolinska Institute, Stockholm, Sweden, and also as a Sloan Fellow at the Maryland Psychiatric Research Center in the USA. Later he organized a Clinical Pharmacology research group at the National Institute of Oncology in Hungary and spent a sabbatical year at the Cancer Center of the Wayne State University, Detroit, USA. He obtained a Doctor of Science degree from the Hungarian Academy of Sciences.
Dr Kerpel-Fronius worked extensively in Clinical Drug Development at the Hungarian National Institute of Oncology and later within the international pharmaceutical industry in Europe. In 2001 he became Professor of Clinical Pharmacology at the Department of Pharmacology and Pharmacotherapy of the Semmelweis University. For a short time he also worked as the General Director of the Hungarian Drug Regulatory Agency (Hungarian National Institute of Pharmacy).
In addition to his academic activities, Dr Kerpel-Fronius is a member of the PharmaTrain Federation and he serves as Vice President of the Alliance for Clinical Research of Excellence and Safety (ACRES). For several years he was a member of the Educational Subcommittee of the European Association for Clinical Pharmacology and Therapeutics, the Executive Board of IMI-PharmaTrain and an invited expert of the OECD Governance of Clinical Trials (OECD: Organisation for Economic Co-operation and Development). In 2016 he was elected Honorary Fellow of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FFPM).
As a pharmaceutical physician, Dr Stonier has over 35 years experience in Medicines Development, Clinical Research, Life-cycle Management and Drug Safety/Pharmacovigilance. From 1977 to 2000 he was Medical Adviser, Medical Director and board member of the Hoechst Marion Roussel group of companies, UK (now Sanofi), and from 2004 to 2013 Group Medical Director and QPPV (Qualified Person for Pharmacovigilance) of Amdipharm plc.
Dr Stonier is Director of Education and Training at the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom and National Programme Director for Pharmaceutical Medicine Specialty Training for Pharmaceutical and Regulatory Physicians in the UK. He is a Board Member of the PharmaTrain Federation, developing and introducing internationally a platform of education and training for all in Medicines Development/Clinical Research: Industry, academia, Clinical Trial Investigators.
Dr Stonier was a founding Fellow of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians UK in 1989 and, with others, made a major contribution to achieving recognition and legal listing for the medical speciality of Pharmaceutical Medicine in 2002.
Dr Stonier is Visiting Professor in Pharmaceutical Medicine at King’s College London, UK, at the Faculty of Life Sciences and Medicine. Whilst previously Visiting Professor at the University of Surrey, UK, the first Masters programme (MSc) in Pharmaceutical Medicine/Medicines Development was introduced under his co-direction.
Dr Stonier is a past President of the FPM, a past President of IFAPP and a past President of the Royal Society of Medicine’s Section for Pharmaceutical Medicine and Research.
Dr Stonier graduated in Physiology (BSc 1st Hons) with a PhD in protein chemistry (inborn errors of metabolism), at the Universities of Birmingham and Sheffield, UK, in 1969. He studied medicine at the Manchester Medical School, UK, qualifying with honors in 1974. His publications include texts in Pharmaceutical Medicine and edited works in Human Psychopharmacology, Clinical Research, Medical Affairs and careers within the pharmaceutical sector.